After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died ...

The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

Some experts worry that patient groups’ growing influence is leading to the approval of drugs that may not work and could ...

It’s been a whirlwind year so far for Sarepta and for Elevidys, which is the only FDA-approved gene therapy for Duchenne. The first fatality associated with this gene therapy was reported in March.

Sarepta Therapeutics is trading around $19 in extended hours following the FDA’s decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech.